* Conmed Corp CNMD.N CNMD.K is expected to show a rise
in
quarterly revenue when it reports results on February 2.
* The Largo Florida-based company is expected to report a
10.4% increase in revenue to $302.513 million from $273.97
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. The company's guidance on
October 26 2022, for the period ended December 31, was for
revenue between $305.00 million and $320.00 million.
* Refinitiv's mean analyst estimate for Conmed Corp is for
earnings of 90 cents per share. The company's EPS guidance on
October 26 2022, for the period ended December 31, was between
$0.98 and $1.05
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Conmed Corp
is
$103, above its last closing price of $93.91.
The company's guidance on October 26 2022 for the period ended
December 31 was for gross profit margin of USD55%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.75 0.75 0.77 Beat 2.4
Jun. 30 2022 0.74 0.75 0.76 Beat 1.8
Mar. 31 2022 0.62 0.62 0.70 Beat 13.3
Dec. 31 2021 1.03 1.03 1.07 Beat 4
Sep. 0.75 0.75 0.80 Beat 6.7
30 2021
Jun. 30 2021 0.62 0.62 0.71 Beat 14.5
Mar. 31 2021 0.44 0.44 0.63 Beat 44.3
Dec. 31 2020 0.78 0.76 0.84 Beat 9.9
This summary was machine generated January 31 at 21:24 GMT. All
figures in US dollars unless otherwise stated